Fig. 1.

Consort diagram. *Eighteen patients received 2 lines of immunotherapy as follows: 8 received ipilimumab then pembrolizumab, 6 pembrolizumab then ipilimumab, 3 ipilimumab then nivolumab, and 1 pembrolizumab then nivolumab. Three patients received 3 lines of immunotherapy as follows: 2 received ipilimumab then pembrolizumab then nivolumab and 1 pembrolizumab then ipilimumab then nivolumab. ipi ipilimumab, nivo nivolumab, pembro pembrolizumab